Residency · Residency · Chronic Pain Management
Cannabis and Cannabinoids for Chronic Pain
Introduction
The therapeutic use of cannabis and cannabinoids for chronic pain has become one of the most debated topics in pain medicine. Despite chronic pain being the most common qualifying condition for medical cannabis programs across US states, the evidence base remains limited by federal scheduling barriers, heterogeneous products, and methodological challenges. Pain medicine specialists must understand endocannabinoid pharmacology, critically evaluate the available evidence, and navigate the complex intersection of state-legal programs and federal prohibition.
The Endocannabinoid System
Components
The endocannabinoid system comprises two primary receptors, two main endogenous ligands, and the enzymes that regulate them. CB1 receptors are predominantly expressed in the central nervous system -- the cortex, basal ganglia, hippocampus, cerebellum, and spinal cord dorsal horn -- and are also present in peripheral nerves and non-neuronal tissues. CB2 receptors are primarily expressed on immune cells (microglia, macrophages, lymphocytes), are upregulated during inflammation and tissue injury, and have sparse CNS expression under normal conditions.
The two principal endogenous ligands are anandamide (AEA) and 2-arachidonoylglycerol (2-AG), both lipid-derived molecules synthesized on demand from membrane phospholipids rather than stored in vesicles. Fatty acid amide hydrolase (FAAH) degrades anandamide, and monoacylglycerol lipase (MAGL) degrades 2-AG. A distinctive feature of endocannabinoid signaling is that it operates in reverse: endocannabinoids are released from the postsynaptic neuron and act on presynaptic CB1 receptors to inhibit neurotransmitter release, including glutamate, GABA, and glycine.
Role in Pain Modulation
The endocannabinoid system modulates pain at multiple levels. At the supraspinal level, CB1 activation in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) modulates descending pain inhibition. At the spinal level, CB1 receptors on primary afferent terminals and dorsal horn interneurons reduce nociceptive transmission. At the peripheral level, CB1 and CB2 receptors on nociceptors and immune cells modulate inflammatory and neuropathic pain. The endocannabinoid system also interacts with opioid, serotonin, and vanilloid (TRPV1) receptor systems. A hypothesis of clinical endocannabinoid deficiency has been proposed as a mechanism underlying fibromyalgia, migraine, and irritable bowel syndrome, though this remains unproven.
<image>Detailed diagram of the endocannabinoid system in pain modulation showing three levels: supraspinal (PAG and RVM with CB1 receptors modulating descending inhibition), spinal dorsal horn (presynaptic CB1 receptors on primary afferent C-fiber terminals reducing glutamate and substance P release, with postsynaptic endocannabinoid synthesis and retrograde signaling), and peripheral (CB1 on nociceptor terminals and CB2 on immune cells at site of tissue injury reducing inflammatory mediator release), with molecular structures of anandamide and 2-AG shown alongside their synthetic and degradative enzyme pathways.</image>
THC vs CBD Pharmacology
Delta-9-Tetrahydrocannabinol (THC)
THC is a partial agonist at both CB1 and CB2 receptors and is the component responsible for psychoactive effects. It has analgesic, antiemetic, appetite-stimulating, and muscle-relaxant properties. Side effects include euphoria or dysphoria, cognitive impairment, anxiety, tachycardia, dry mouth, and impaired driving. Tolerance develops to most side effects (sedation, psychomotor impairment) but less so to the analgesic effects. THC's half-life ranges from 1-3 days in occasional users to 5-13 days in chronic users due to lipophilic tissue accumulation. It is metabolized by CYP2C9 and CYP3A4 to the active metabolite 11-OH-THC and the inactive metabolite 11-COOH-THC.
Cannabidiol (CBD)
CBD has no significant CB1 or CB2 agonist activity, and its mechanism of action is complex and multifactorial. It acts as a negative allosteric modulator at CB1 (potentially attenuating THC effects), agonizes 5-HT1A receptors (producing anxiolytic effects), desensitizes TRPV1 channels, and acts on GPR55 (anti-inflammatory). It also inhibits FAAH, indirectly increasing endogenous anandamide levels. CBD has anti-inflammatory, anxiolytic, anticonvulsant, and potentially analgesic properties, with no psychoactive effects and no abuse potential according to a WHO report. Importantly, CBD inhibits CYP3A4 and CYP2D6, creating clinically significant drug interactions with opioids, benzodiazepines, and warfarin. The only FDA-approved CBD formulation is Epidiolex (cannabidiol oral solution) for seizure disorders.
| Product | Active Ingredient | Approved Indications | Route | THC:CBD Ratio | US FDA Status |
|---|---|---|---|---|---|
| Dronabinol (Marinol) | Synthetic THC | CINV; AIDS anorexia | Oral capsule | Pure THC | FDA-approved |
| Nabilone (Cesamet) | Synthetic THC analog | CINV | Oral capsule | Pure THC analog | FDA-approved |
| Nabiximols (Sativex) | THC + CBD (plant-derived) | MS spasticity | Oromucosal spray | 1:1 | Not FDA-approved (approved in Canada/Europe) |
| Epidiolex | CBD (plant-derived) | Seizure disorders (Dravet, Lennox-Gastaut) | Oral solution | Pure CBD | FDA-approved |
Pharmaceutical Cannabinoids
Dronabinol (Marinol) is synthetic THC approved for chemotherapy-induced nausea and AIDS-related anorexia. Nabilone (Cesamet) is a synthetic THC analog approved for chemotherapy-induced nausea and studied in fibromyalgia and neuropathic pain. Nabiximols (Sativex) is a 1:1 THC:CBD oromucosal spray approved in Canada and Europe for MS-related spasticity but not FDA-approved in the US.
Evidence for Chronic Pain Indications
Neuropathic Pain
Neuropathic pain is the best-supported indication for cannabinoid analgesia. The 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) report found substantial evidence that cannabis is effective for chronic pain in adults, with the strongest data for neuropathic pain. Inhaled cannabis showed short-term analgesic benefit in neuropathic pain RCTs, with a number needed to treat of approximately 5-6 for 30% pain reduction. Nabiximols showed modest benefit for central neuropathic pain in MS but mixed results for peripheral neuropathic pain. Effect sizes are generally small to moderate, comparable to existing neuropathic pain medications.
Spasticity
Moderate evidence supports nabiximols for MS-related spasticity, though patient-reported spasticity improvement is more consistent than objective spasticity measures. Nabiximols is a recommended second-line therapy in several international MS treatment guidelines.
Other Pain Conditions
For fibromyalgia, small trials of nabilone and medical cannabis show mixed results, and the evidence is insufficient for a recommendation. For cancer pain, nabiximols as an adjunct to opioids showed modest benefit in some but not all Phase III trials and is currently a third-line option. For inflammatory arthritis, there is preliminary evidence for CBD's anti-inflammatory properties but no definitive RCT data. For headache disorders, only anecdotal and survey data exist without controlled trial evidence. For chronic low back pain, the evidence from controlled trials is insufficient.
<image>Evidence heat map for cannabinoid therapies across chronic pain conditions, organized as a matrix with pain conditions on the vertical axis (neuropathic pain, MS spasticity, cancer pain, fibromyalgia, chronic low back pain, headache, osteoarthritis) and cannabinoid types on the horizontal axis (inhaled cannabis, oral THC, nabiximols 1:1 THC:CBD, CBD alone, synthetic cannabinoids), with cells color-coded from green (substantial evidence) through yellow (moderate evidence), orange (limited evidence), to red (insufficient evidence), and annotations showing NNT values where available and key study citations for each cell.</image>
State-Legal Medical Cannabis Programs
Program Structure
As of 2026, over 40 states have operational medical cannabis programs with varying qualifying conditions. Chronic pain is a qualifying condition in the majority of programs and is often the most common reason for certification. Programs typically require physician certification (not a prescription) that the patient has a qualifying condition. Physicians do not select specific products, strains, or doses; patients access dispensaries independently. Registry participation varies by state, with some requiring patient registration cards.
Program Variability
Product availability varies widely and may include flower, concentrates, tinctures, edibles, topicals, and suppositories. Some states cap THC content or require minimum CBD:THC ratios. Testing requirements for contaminants (pesticides, heavy metals, microbials) and potency verification differ across states. Home cultivation is permitted in some states, creating additional quality control challenges. There is no federal regulation of product quality, standardization, or labeling accuracy.
Prescriber Considerations
Legal and Professional Risk
Cannabis remains Schedule I under the Controlled Substances Act, and federal law does not recognize medical use. Physicians certify rather than prescribe medical cannabis, a distinction that provides some legal protection. The DEA has not historically targeted physicians acting in compliance with state programs, but the legal risk is nonzero. State medical board positions vary: some explicitly protect certifying physicians while others are ambiguous. Documentation should reflect a bona fide physician-patient relationship, examination, informed consent, and ongoing monitoring.
Clinical Guidance for Recommending Patients
Cannabis should generally be considered after failure of first- and second-line evidence-based treatments. Start with low THC doses (2.5-5 mg) and titrate slowly -- "start low, go slow." CBD-predominant or balanced THC:CBD products may offer better tolerability profiles. Smoked cannabis should be avoided when possible; vaporization, oral, and sublingual routes are preferred. Patients should be monitored for cognitive impairment, cannabis use disorder (9% lifetime risk, higher in daily users), and psychiatric exacerbation (anxiety, psychosis risk in predisposed individuals). CBD's inhibition of CYP3A4 and CYP2D6 can affect opioid, benzodiazepine, and warfarin metabolism. Contraindications include personal or family history of psychotic disorders, pregnancy, adolescent brain development concerns, and unstable cardiovascular disease.
Driving and Occupational Considerations
THC impairs driving performance, and there is no validated equivalent of blood alcohol level for impairment assessment. Patients should be counseled about state DUI laws and occupational drug testing policies. Federal employees and safety-sensitive positions (DOT-regulated) are prohibited from using cannabis regardless of state law.
<image>Clinical decision framework flowchart for medical cannabis certification in chronic pain, starting with confirmed chronic pain diagnosis and documentation of failed conventional therapies, proceeding through risk assessment (screening for cannabis use disorder risk, psychiatric history, pregnancy, age), then product and route selection guidance (CBD-predominant for low risk tolerance, balanced THC:CBD for moderate pain, THC-predominant as last resort), dosing initiation protocol (start low go slow with specific mg recommendations), and monitoring plan (follow-up at 1 month, then quarterly, assessing pain scores, functional outcomes, adverse effects, signs of cannabis use disorder), with exit ramps at each decision point for patients who are not appropriate candidates.</image>
Clinical Pearls
Neuropathic pain has the strongest evidence supporting cannabinoid analgesia; evidence for other chronic pain conditions is limited or mixed. CBD is not pharmacologically inert -- it has clinically significant CYP3A4 and CYP2D6 inhibition that can alter metabolism of opioids, benzodiazepines, and other medications. The risk of cannabis use disorder is approximately 9% with any use and increases to 25-50% with daily use, so screening and monitoring are essential. Over-the-counter CBD products are unregulated and frequently mislabeled in terms of CBD content, and they may contain undisclosed THC. Pain medicine specialists should be knowledgeable about cannabinoid pharmacology regardless of personal prescribing stance, because patients are already using these products and need evidence-based guidance.
References
- National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017.
- Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755-E796.
- Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932-1954.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473.
